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In endothelial cells Tumor Necrosis Factor-α (TNFα) stimulates arginine transport through the increased expression of SLC7A2/CAT2
transcripts. Here we show that also rapamycin, an inhibitor of mTOR kinase, stimulates system y+-mediated arginine uptake in human endothelial
cells derived from either saphenous (HSVECs) or umbilical veins (HUVECs). When used together with TNFα, rapamycin produces an additive
stimulation of arginine transport in both cell models. These effects are observed also upon incubation with AICAR, a stimulator of Adenosine-
Monophosphate-dependent-Protein Kinase (AMPK) that produces a rapamycin-independent inhibition of the mTOR pathway. Rapamycin
increases the Vmax of high affinity arginine transport and causes the appearance of a low affinity component that is particularly evident if the
treatment is carried out in the presence of TNFα. RT-qPCR studies have demonstrated that these kinetic changes correspond to the induction of
both the high affinity transporter CAT2B and the low affinity isoform CAT2A. Western blot and immunocytochemical analyses indicate that,
consistently, the expression of CAT2 proteins is also stimulated under the same conditions. These changes are associated with an increase of the
intracellular arginine concentration but with a decrease of NO production. Thus, our data suggest that mTOR activity is associated with the
repression of CAT2 expression at mRNA and protein level.
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doi:10.1016/j.bbamem.2007.02.016ubiquitous CAT1, encoded by SLC7A1, and the two transpor-
ters, CAT2A and CAT2B, derived from alternative splicing of
SLC7A2 transcripts, are the best characterized members of the
family [2,3]. Conversely, system y+L is a member of the group
of heterodimeric amino acid transporters (see [4] for review),
formed by a light and a heavy subunit. In the case of system
y+L, the heavy subunit is 4F2hc/CD98, the product of SLC3A2
gene, while two alternative light chains have thus far been
characterized, y+LAT1 (encoded by SLC7A7) and y+LAT2
(encoded by SLC7A6).
While a regulatory mechanism for system y+L expression
has been described only for human monocytes [5], the
regulation of CAT expression and transport activity has been
extensively studied under a variety of hormonal and inflamma-
tory stimuli. In particular, proinflammatory cytokines modulate
cationic amino acid transport activity in several endothelial cell
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have demonstrated that TNFα enhances system y+ activity
through an increase of CAT2B expression, while the activity
and the expression of system y+L are not changed by the
cytokine [1]. The transduction pathway employed by TNFα to
induce the increase of arginine transport has been partially
characterized in Human Saphenous Vein Endothelial Cells
(HSVECs) [8]. Those results demonstrated that the activation of
NF-κB is required for the TNFα effect on CAA transport, while
the involvement of other transduction pathways, such as PKC
and MAPK, was excluded [8]. However, given the complexity
of TNFα-dependent signalling pathways, it is apparent that
other transduction routes may be involved in the cytokine-
dependent stimulation of arginine transport.
Among the possible candidates, the PI3K/Akt/mTOR path-
way appears of great interest since it is known that TNFα
activates PI3K and Akt in human endothelial cells [9] and,
hence, is expected to raise the activity of mTOR (mammalian
Target Of Rapamycin). Consistently, TNFα-dependent stimula-
tion of PI3K effectors, including Akt, activates mTOR in non-
endothelial models [10,11]. mTOR, known also as FRAP or
RAFT, is a serine/treonine kinase that plays an important role in
the regulation of cell growth and proliferation, nutrient
transport, protein and RNA stability, acting as a fundamental
controller of protein translation [12–14]. Studies about mTOR
functions have been greatly favored by the availability of a
specific inhibitor, rapamycin (sirolimus), a macrolide antibiotic,
isolated from Streptomyces hygroscopicus, that specifically
inhibits mTOR activity after binding to the protein FKBP12
[15].
In this study, we demonstrate that rapamycin stimulates
SLC7A2 gene expression, thus leading to the enhanced
expression of CAT2 transporters and to the stimulation of
arginine transport. Moreover, we provide evidence that the
rapamycin and TNFα effects on arginine transport are additive.
1. Materials and methods
1.1. Cells and experimental treatments
HSVECs were obtained from vessel remnants of patients undergoing
coronary artery bypass grafting and cultured as already described [8]. Five
strains of HSVECs from different patients were employed with qualitatively
similar results. HUVECs were obtained from three distinct cords according to
the method of Jaffe, with minor modifications as described previously [16].
Cells were routinely grown in collagen-coated, 10-cm diameter dishes in
medium 199 (M199), with glutamine concentration raised to 2 mM. The culture
medium was supplemented with 20% fetal bovine serum (FBS), endothelial cell
growth supplement (ECGS, 37.5 μg/ml), and heparin (75 U/ml). Cells were kept
at 37 °C, pH 7.4, in an atmosphere of 5% CO2. Cultures consisted of
homogeneous endothelial populations, as demonstrated by the typical
cobblestone morphology and the positivity to von Willebrand's factor and
CD31/PECAM-1 antigens. Culture mediumwas always renewed 24 h before the
experiment.
Cells were employed 2–3 days after seeding, when cultures were almost
confluent (12±3 g of protein/cm2). Unless otherwise stated, TNFα was used at
10 ng/ml in complete growth medium from a 100× stock in sterile water for the
times indicated for each experiment. Rapamycin (100 nM) and 5-aminoimida-
zole-4-carboxamide-1-b-D-ribofuranosyl 3′-5′-cyclic-monophosphate (AICAR,
2 mM) were added 1 h before the cytokine treatment from 100× stocks in growth
medium.1.2. Arginine influx
For transport studies, cells were seeded on 2-cm2 wells of disposable Falcon
24-well trays (Becton Dickinson Labware Europe, Le Pont De Claix, France) in
1 ml of growth medium. All the experiments were performed using the cluster-
tray method for the measurement of solute fluxes in adherent cells [17] with
appropriate modifications. Cell monolayers were washed twice in Earle's
balanced salt solution (EBSS), containing (in mM) 117 NaCl, 26 NaHCO3, 5
KCl, 1.8 CaCl2, 1 NaH2PO4, 0.8 MgSO4, 5.5 glucose. L-Arginine influx was
assayed with a 30 s incubation of the cells in the same solution containing L-[3H]
arginine. Preliminary experiments indicated that, in this interval, arginine influx
approached linearity under all the experimental conditions adopted (results not
shown). To restrict arginine uptake to CAT transporters (system y+), the activity
of system y+L was inhibited adding leucine to the uptake solution [1]. The
experiments were terminated by two rapid washes (<10 s) in ice cold 0.3M urea.
Cell monolayers were extracted in 0.2 ml ethanol and the radioactivity of
extracts was determined with a Wallac Microbeta Trilux (Perkin Elmer,
Wellesley, Ma, USA). Extracted cell monolayers were then dissolved with 0.5%
sodium deoxycholate in 1 M NaOH and protein content was determined directly
in each well using a modified Lowry procedure as previously described [17].
Amino acid influx is expressed as nmoles·mg of protein−1·min−1. Kinetic
parameters of arginine influx were determined by non-linear regression analysis
using a GraphPad Prism3™ software. The equations used for fitting the
experimental data were:
v ¼ Vmaxd ½S
Km þ ½S ð1Þ
for a single saturable system, or
V ¼ Vmax1d ½S
Km1 þ ½S þ
Vmax2d ½S
Km2 þ ½S ð2Þ
for two saturable systems, where v is the initial influx, Vmax the maximal influx
and Km the Michaelis constant.
1.3. RT-qPolymerase chain reaction
1 μg of total RNA, isolated with RNeasy Mini Kit® (Qiagen S.p.a., Milano,
Italy), was reverse transcribed as described previously [1]. For real time PCR (40
cycles), cDNA was amplified with 2X Platinum® SYBR® Green qPCR
SuperMix-UDG (Invitrogen s.r.l., Milano, Italy), along with the following
forward and reverse primers (5 pmol each): 5′ CTT CAT CAC CGG CTG GAA
CT 3′ and 5′ GGG TCT GCC TAT CAG CTC GT 3′ for SLC7A1/CAT1; 5′
TTC TCT CTG CGC CTT GTC AA 3′ and 5′ TCTAAA CAG TAA GCC ATC
CCG G 3′ for SLC7A2/CAT2A; 5′ TTC TCT CTGCGC CTT GTC AA 3′ and
5′ CCATCC TCC GCC ATA GCATA 3′ for SLC7A2/CAT2B; 5′ AGC CTC
AAG ATC ATC AGC AAT G 3′ and 5′ CAC GATACC AAA GTT GTC ATG
GA 3′ for GAPDH. The primer set was designed according to the known
sequences reported in GenBank with the help of Primer 3 program [18].
Quantitative PCR was performed in a 36 well Rotor Gene 3000 (Corbett
Research, Rotor-Gene™ 3000, version 5.0.60, Mortlake, Australia). Each cycle
consisted of a denaturation step at 95 °C for 15 s, followed by separate annealing
(30 s, 57 °C) and extension (30 s, 72 °C) steps. Fluorescence was monitored at
the end of each extension step. A no-template, no-reverse transcriptase control
was included in each experiment. At the end of the amplification cycles a
melting curve analysis was added. The analysis of the data was made according
to the Relative Standard Curve Method [19].
1.4. Western analysis
Cells, grown in 10-cm2 dishes, were washed twice with ice-cold phosphate-
buffered saline, scraped in the same solution and collected by low speed
centrifugation. The pellet was suspended in 0.3 ml of Laemmli buffer (62.5 M
Tris–HCl, pH 6.8, 2% SDS, 20%glycerol, 0.2MDTT). For the analysis of CAT2,
DNAwas sheared by passing repeatedly the sample through 22G and 27G needles
until the viscosity dropped [20]. After total protein quantification by a modified
micro Lowry protein assay, 30 μg of protein samples were separated on 8%
Fig. 1. Effect of rapamycin and TNFα on arginine transport in HUVECs and
HSVECs. Cells were incubated in the absence or in the presence of 10 ng/ml
TNFα, 100 nM rapamycin, or both, as indicated. After 8 h or 24 h cells were
washed in EBSS and L-arginine influx was assayed with 30-s incubations in
the same solution supplemented with [3H]arginine (100 μM; 4 μCi/ml) in the
presence of 2 mM L-leucine to restrict arginine influx to system y+. Bars are
means±SEM of eight experiments on three different HUVEC strains and
seven experiments on 5 distinct HSVEC strains. ∗∗p<0.01, ∗∗∗p<0.001 vs.
control, untreated cells; #p<0.05, ###p<0.001 vs. cells treated with TNFα;
$p<0.05, $$p<0.01, $$$p<0.001 vs. cells treated with rapamycin.
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polyvinylidene difluoride (PVDF) membrane (Bio Rad, Milano, Italy). Mem-
branes were blocked at 4 °C overnight with an incubation in Tris-buffer saline
(TBS; 50 mMTris–HCl pH 7.5, 150 mMNaCl), containing 3%BSA, 1%Casein,
0.33% gelatin and 10% goat serum and exposed for 2 h at room temperature to a
filtered anti-hCAT2 polyclonal antiserum (diluted 1:2000 in blocking solution).
This antiserum was generated by Neosystem Groupe SNPE (Strasbourg, France)
against the C-terminus peptide Y-17-F (Y-R-N-L-S-S-P-F-I-F-H-E-K-T-S-E-F)
of human CAT2 proteins. The blot was then exposed to horseradish peroxidase-
conjugated anti-rabbit IgG (1:3000) for 1 h at room temperature. The membranes
were washed and the immunoreactivity visualized with enhanced chemilumines-
cence (Bio Rad, Milano, Italy). The expression of p70S6 kinase and of phospho-
p70S6 kinase was determined as described by PhosphoPlus® p70S6 kinase
(Thr389, Thr421/Ser424) Antibody kit from Cell Signaling (Celbio, Milano,
Italy). β-Tubulin and GAPDH, detected with a monoclonal antiserum (1:50 and
1:500, respectively), were employed for standardization.
1.5. Immunocytochemistry
Immunostaining for CAT2 was performed on cell monolayers grown on
Falcon two-well chamber slides (Becton Dickinson Labware Europe, Le Pont
De Claix, France). Cells, after a 24 h incubation in the indicated media, were
washed twice with PBS and fixed with 3.7% paraformaldehyde in PBS (pH 7.4).
After additional washing, non-specific absorption of antibodies was blocked by
incubation for 1 h in PBS containing 3% bovine serum albumin after which the
cells were incubated for 1 h at 37 °C with anti-CAT2 polyclonal antiserum (see
Western analysis) diluted 1:500 in blocking solution. After three washing, cells
were incubated for 1 h at room temperature with Alexa Fluor 488–conjugated
secondary antibodies (Molecular Probes, Invitrogen, Milano, Italy) (1:400
dilution in blocking solution). The cells were finally washed, and the slides were
mounted with Pro-Long® antifade kit (Molecular Probes, Invitrogen, Milano,
Italy), and examined with a confocal microscope ZEISS, LSM 510 META
equipped with inverted microscope Axiovert 200 M Carl Zeiss Meditec GmbH,
Munchen-Hallbergmoos, Germany. For each condition, a series of confocal
images of representative fields were taken and the section yielding the maximal
signal was selected.
1.6. Determination of amino acid content and NO production
The intracellular content of lysine and arginine was determined on cell
extracts in a 5% solution of acetic acid in ethanol by HPLC analysis with a
Biochrom 20 Amino Acid Analyzer (Biochrom, Cambrige, UK) employing a
High Resolution Column Bio 20 Peek Lithium and the Physiological Fluid
Chemical Kit (Biochrom, Cambrige, UK) for elution. The column effluent was
mixed with ninhydrin reagent, passed through the high temperature reaction
coil, and read by the photometer unit. The intracellular concentration of amino
acids was calculated from the amino acid contents (expressed in nmol/mg of
protein) and cell volumes determined in parallel cultures under the same
experimental conditions by [14C] urea distribution, as described previously [21].
The accumulation of nitrite, stable derivative of NO, in the culture media of
HUVECs was assessed through a fluorimetric approach, based upon the
production of the fluorescent molecule 1-(H)-naphtotriazole from DAN in the
presence of nitrite in an acid environment [22] as described previously [1].
Fluorescence was determined with Wallac Victor2 1420 Multilabel Counter
(Perkin Elmer, Wellesley, Ma, USA). Nitrite production was expressed in
nmoles per ml of extracellular medium (μM).
1.7. Statistical analysis
Unless otherwise specified, statistical analysis of data was performed with a
one-way ANOVA with the Bonferroni post hoc test. P values >0.05 were
considered not significant.
1.8. Materials
Endotoxin-free FBS and Medium 199 (Euroclone) were purchased from
Celbio (Pero, MI, Italy). L-[2,3,4-3H]Arginine (45–70 Ci/mmol) was obtainedfrom Perkin Elmer (Monza, Italy), TNFα (Alexis) from Vinci-Biochem
(Firenze, Italy). Horseradish peroxidase-conjugated anti-rabbit IgG and anti-
βTubulin antibodies (Santa Cruz Biotechnology) were purchased from DBA
Italia (Milano, Italy), while GAPDH (Chemicon) was obtained from Prodotti
Gianni (Milano, Italy). Sigma (Milano, Italy) was the source of rapamycin and
AICAR, as well as of all other chemicals.
2. Results
2.1. Rapamycin and TNFα additively stimulate arginine
transport
The effect of rapamycin on arginine transport through system
y+ is shown in Fig. 1. The experiments were performed in
HUVECs and in HSVECs in the absence or in the presence of
TNFα that, as expected [1,8], significantly stimulated system y+
activity in both cell types. In the absence of TNFα, rapamycin
(100 nM) significantly stimulated arginine transport in HUVECs
after either 8 or 24 h of treatment. In HSVECs the rapamycin-
dependent stimulation of arginine transport was somewhat
dependent on the cell strain, ranging from +10% to +50%.
However, when simultaneously treated with rapamycin and
TNFα, both HUVECs and HSVECs consistently exhibited
values of arginine transport markedly higher than those obtained
with either compound alone. Indeed, in cells incubated for 8 h or
24 h in the presence of both TNFα and rapamycin, system y+-
mediated arginine transport increased by 2- or 3-fold compared
with untreated, control cells.
Fig. 2 shows the transport activity of system y+ in HUVECs
treated with different concentrations of TNFα in the absence or
in the presence of rapamycin. TNFα-dependent stimulation of
arginine transport was significant at 1 ng/ml and maximal at
10 ng/ml, with no further increases at higher cytokine
concentrations. In all the range of cytokine concentrations
tested (from 0.1 to 100 ng/ml), cells treated with both rapamycin
Fig. 2. Dose–response curve of TNFα effects on arginine transport in the
absence and in the presence of rapamycin. HUVECs were incubated for 20 h
with the indicated concentrations of TNFα in the absence (empty bars) or in the
presence (solid bars) of 100 nM rapamycin. After this period, cells were washed
in EBSS and system y+ transport activity was measured as described in the
legend of Fig. 1. Points are means of three independent determinations within
one representative experiment with SD indicated. The experiment was repeated
twice with similar results. Statistical analysis was performed with two-tail t-test
for unpaired data. ∗∗∗p<0.001, ∗∗p<0.01, ∗p<0.05 vs. cells incubated with the
same TNFα concentration in the absence of rapamycin.
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treated with the cytokine alone.
A kinetic analysis of arginine transport, employing a wide
range of amino acid concentrations, was performed with
untreated HSVECs or with cells treated for 24 h in the
presence of TNFα and rapamycin. (Fig. 3). Uptake was
measured in the presence of excess extracellular leucine (seeFig. 3. Kinetic analysis of L-arginine transport in HSVECs: effect of the combined tre
(control) or in the presence of TNFα+rapamycin. After this period, the 30 s influx o
presence of 2.5 mM (for [Arg] from 0.016 to 0.256 mM) or 25 mM L-leucine (for [A
means of three independent determinations within one representative experiment repe
data to Eq. (1) for control cells or to Eq. (2) for TNFα+rapamycin-treated cells (see M
concentrations up to 1 mM (control, untreated cells) are represented in an amplified sc
representation. In the inset, data of arginine influx obtained in control, untreated cells a
obtained from the non-linear regression analysis shown in Panel A.the legend) to inhibit system y+L. The diffusive component (Kd
of 0.95±0.02 min−1), derived from the linear regression of
influx values at high arginine concentrations (from 2 to 10 mM)
in control cells, was subtracted to influx data to yield the
saturable arginine influx. The results are presented both in v vs.
[S] representation (Panel A) and in the Eadie–Hofstee graphical
transformation (Panel B) so as to allow a better discrimination
between the transport components. Saturable arginine transport
in untreated cells was satisfactorily fitted with a single system
(Km=0.08±0.027 mM, Vmax of 2.51±0.18 nmol/mg of
protein/min, R2 =0.88, see the insets of Panels A and B). On
the contrary, in cells treated with TNFα and rapamycin,
transport data were best fitted (R2 =0.99) by the operation of
two saturable transport systems with very divergent affinities
(see Panel B): the high affinity component whose Vmax was
markedly increased (10.4±1.85 nmol/mg of protein/min) while
the Km (0.12±0.036 mM) was not significantly modified and a
low affinity component, not detectable in control cells, with a
Vmax of 27.34±2.7 nmol/mg of protein/min and a Km of 5±
1.56 mM. While the Km of the high affinity component is in the
range attributed to the high affinity system y+-related CAT
isoforms (CAT1 and CAT2B), the Km of the low affinity
component is compatible with the operation of CAT2A
transporter [2]. Similar analyses indicated that incubation
with TNFα or rapamycin alone raised the Vmax of the high
affinity component and caused the appearance of the low
affinity component, although at a lesser extent than the two
compounds together (results not shown).atment with rapamycin and TNFα. Cells were incubated for 24 h in the absence
f increasing concentrations of L-[3H]Arg (0.016 −10 mM) was measured in the
rg] from 0.64 to 10 mM). Influx data were corrected for Kd (see text). Points are
ated twice with comparable results. Panel A, Curves represent the best fit of the
aterials and methods). In the inset, data of arginine influx obtained with arginine
ale. Panel B, Data reported in Panel A are shown in the Eadie–Hofstee graphical
re represented in an amplified scale. Lines are drawn from the kinetic parameters
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due to the induction of CAT2 mRNAs and proteins
To investigate the mechanism underlying the changes of
arginine transport in HUVECs treated with TNFα, rapamycin,
or both compounds, we performed a real time PCR analysis of
the expression of SLC7A1, coding for the constitutive CAT1Fig. 4. Effect of rapamycin and TNFα on the expression of genes related to
system y+ in HUVECs. Cells were incubated for 8 h or 24 h in the absence or in
the presence of 10 ng/ml TNFα, 100 nM rapamycin, or TNFα+rapamycin, as
indicated. After RNA extraction and reverse transcription, cDNAwas employed
as template for qPCR with CAT1, CAT2A, CAT2B, or GAPDH primers (see
Materials and methods). The intensity of the SLC7A1/CAT1, (Panel A)
SLC7A2/CAT2A (Panel B) and SLC7A2/CAT2B (Panel C) amplification
products was normalized to that of the GAPDH product amplified from the same
cDNA sample and referred to the corresponding value obtained in control,
untreated cells (=1). Data are means±SEM of three separate experiments on 3
distinct HUVEC strains. ∗p<0.05, ∗∗p<0.01, ∗∗∗p<0.001 vs. control,
untreated cells; #p<0.05, ##p<0.01, ###p<0.001 vs. cells treated with TNFα;
$$p<0.01 vs. cells treated with rapamycin.
Fig. 5. Effect of rapamycin and TNFα on CAT2 protein in HUVECs. Cells were
incubated for 24 h in the absence or in the presence of 10 ng/ml TNFα, 100 nM
rapamycin, or both, as indicated. After protein extraction, Western Blot analysis
was performed using anti-CAT2 (1:2000) and anti-β tubulin antisera (1:50, see
Materials and methods). Lower panel presents the results of the densitometric
analysis of CAT2 expression, normalized to β-tubulin expression. A representa-
tive Western blot is shown; the experiment was repeated three times with similar
results.transporter, and SLC7A2, that encodes for two distinct isoforms
of CAT2 transporter, CAT2A and CAT2B [23–25]. The
expression of CAT1 (Fig. 4, Panel A) was comparable under
all the experimental conditions adopted. On the contrary, either
TNFα or rapamycin induced an increase in both CAT2A (Panel
B) and CAT2B expression (Panel C), with rapamycin producing
the largest effect. If rapamycin treatment was performed in the
presence of TNFα, a massive (>5–10 fold) increase in both
CAT2A and CAT2B mRNA levels was consistently observed
after 8h and, even more clearly, after 24 h of incubation.
To assess whether the observed changes of transport activity
and gene expression were associated with changes in protein
levels, the cell content of CAT2 proteins was determined in
HUVECs incubated with TNFα, rapamycin, or both. It should
be noted that the polyclonal antiserum used for these studies
does not discriminate between CAT2A and CAT2B isoforms.
The results of the Western Blot analysis (Fig. 5) indicate
that CAT2 proteins are clearly detectable by the antiserum
used. Marked differences in CAT2 expression among the
experimental conditions adopted are evident. While carrier
proteins were almost undetectable in control, untreated
HUVECs, a 8-fold increase in CAT2 expression was detected
in response to a 24-h treatment with TNFα; under the same
conditions, also rapamycin caused a similar, significant
increase on the expression of CAT2 protein but the largest
induction (20-fold) was detectable in cells treated with both
compounds.
The immunocytochemical analysis of CAT2 expression in
HUVECs, presented in Fig. 6, confirmed these results. While
Fig. 6. Expression of CAT2 proteins in HUVECs. Cells were incubated for 24 h in the absence or in the presence of 10 ng/ml TNFα, 100 nM rapamycin, or both, as
indicated. At this time immunocytochemical analysis was performed with anti-CAT2 antiserum and the slides observed in CLSM. Single confocal sections of
representative fields are shown (see Materials and methods). Arrows, perinuclear areas of high CAT2 expression. Arrowheads, membrane expression of CAT2
proteins.
Fig. 7. Effect of rapamycin and TNFα on the intracellular concentration of
cationic amino acids (Panel A) and NO production (Panel B) in HUVECs. Cells
were incubated in the absence or in the presence of 10 ng/ml TNFα, 100 nM
rapamycin, or both, as indicated. (Panel A) After 24 h cells were washed twice in
PBS and extracted as described under Materials and methods. The amino acid
content of the extracts was determined with HPLC and corrected with the cell
volume, measured in parallel, to yield the intracellular concentrations (see
Materials and methods). Bars represent means of three independent determina-
tions with SEM indicated. (Panel B) After 48 h, the concentration of nitrites in
the incubation medium was determined in parallel cultures as described under
Materials and methods. Bars represent means of six independent determinations
in three experiments with SEM indicated. ∗p<0.05, ∗∗p<0.01 vs. control,
untreated cells.
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became evident in cells treated for 24 h with TNFα or
rapamycin. Interestingly, the confocal sections of treated cells
demonstrate that the carrier proteins localize both at the plasma
membrane and inside the cells, with a particular abundance in
the perinuclear area. Cells treated with both rapamycin and
TNFα uniformly presented a much higher CAT2 signal, both in
the cytoplasm and at the plasma membrane (see arrows).
2.3. The stimulation of arginine transport by rapamycin and
TNFα causes an increase in cell content of cationic amino
acids without a stimulation of NO production
The cell contents of arginine and lysine were determined
with HPLC and corrected for the values of cell volume
measured in parallel to yield the intracellular concentration of
cationic amino acids. The results (Fig. 7, Panel A) indicate that
rapamycin, either alone or together with TNFα, caused a
significant increase in the intracellular concentration of both
lysine and arginine. However, the production of NO, as assessed
with the determination of nitrites in the extracellular medium,
was not increased under any experimental condition but, rather,
1485R. Visigalli et al. / Biochimica et Biophysica Acta 1768 (2007) 1479–1487was significantly lower in cells treated with either TNFα or
rapamycin (Fig. 7, Panel B).
2.4. AICAR stimulates arginine transport
To verify if the effect of rapamycin was detectable also in
other conditions associated with the inhibition of mTOR, we
used AICAR, which activates AMPK (Adenosine-Monopho-
sphate-dependent-Protein Kinase), a rapamycin-independent
inhibitor of mTOR. Fig. 8, Panel A, shows the effects of a
20-h treatment with AICAR on arginine influx in the absence or
presence of TNFα. In the absence of TNFα, AICAR produced a
modest, although significant, stimulation of arginine uptake. In
cells incubated with the AMPK stimulator in the presence of
TNFα, the transport activity was higher than in cells incubated
with TNFα alone. However, the effect of rapamycin was larger
than that of AICAR, both in the absence or in the presence of
TNFα.
To verify if the stimulatory effect of AICAR was associated
with the inhibition of mTOR, we assessed the phosphorylationFig. 8. Effect of rapamycin and AICAR on system y+ transport activity and
p70S6K phosphorylation in HUVECs. Cells were incubated for 20 h in the
absence or in the presence of rapamycin (100 nM) or AICAR (2 mM), as
indicated. (Panel A) The treatments were performed in the absence (left) or in the
presence (right) of TNFα (10 ng/ml). After this period, cells were washed in
EBSS and system y+ transport activity was measured as described in the legend
of Fig. 1. Points are means of three independent determinations within one
representative experiment with SD indicated. The experiment was repeated
twice with two distinct HUVEC strains with similar results. ∗∗p<0.01,
∗∗∗p<0.001 vs. control, untreated cells (left); #p<0.05, ###p<0.001 vs. cells
treated with TNFα (right). (Panel B) After protein extraction, Western blot
analysis was performed using anti-p70S6 kinase, anti-phospho-p70S6 kinase
(Thr389) both at a concentration of 1:1000, and anti-GAPDH antisera (1:500,
see Materials and methods). A representative Western blot is shown. The
experiment was repeated twice with similar results.status of p70S6 kinase, a well known substrate of mTOR kinase.
The results, presented in Fig. 8, Panel B, indicated that AICAR
produced a clear cut inhibition of p70S6 kinase phosphoryla-
tion, although at a lesser degree than rapamycin.
3. Discussion
We have recently demostrated that the stimulation of
arginine transport and CAT2B expression, elicited by TNFα
in human endothelial cells, is associated with the activation of
NF-κB pathway [8]. Since other effects of TNFα have been
attributed to the activation of the PI3-kinase/Akt/mTOR
transduction pathway [26,27], we undertook this study to
establish the role of mTOR in TNFα-dependent stimulation of
system y+. Surprisingly, rapamycin did not inhibit the
stimulation of arginine transport and CAT2 expression by
TNFα but, rather, it significantly enhanced the effect of the
cytokine. Consistent with recently published evidences [28,29],
our results suggest that, in spite of the antagonism described for
rapamycin and TNFα in vascular smooth muscle cells [30], the
effects of the two compounds may actually synergize in
endothelial cells.
Interestingly, rapamycin alone was also able to stimulate
arginine uptake through an increased expression of SLC7A2,
suggesting that the inhibitor relieves a repressive effect of the
mTOR transduction pathway on the gene.
While the molecular mechanisms underlying rapamycin
effect deserve future investigations, they should not be ascribed
to the induction of TNFα production by endothelial cells.
Indeed, although it is known that human endothelial cells are
able to produce this cytokine [31], rapamycin had no significant
effect on its expression in HUVECs (Barilli, A., results not
shown). Moreover, the dose–response curve for TNFα-
dependent stimulation of arginine transport, shown in Fig. 2,
indicates that at 10 ng/ml the effect of the cytokine is maximal
but still further enhanced by rapamycin.
It should be stressed that SLC7A2 induction seems due to
mTOR inhibition rather than to a specific effect of rapamycin.
Indeed, a condition that leads to an indirect, rapamycin-
independent inhibition of the kinase, such as treatment with
AICAR, also causes the stimulation of arginine uptake either in
the presence or in the absence of TNFα (see Fig. 8).
The expression of CAT2 transporters was studied here also at
the protein level using a polyclonal anti-CAT2 antibody. This
antiserum is apparently CAT2-specific and does not seem to
interact with CAT1 since with either Western blot or
immunocytochemical analysis a signal is detectable only in
cells treated with TNFα, rapamycin, or both, that is, under
conditions in which only the expression of SLC7A2 is
stimulated. With this antiserum we have demonstrated that
rapamycin-dependent stimulation of arginine transport in
endothelial cells seems quite a straight forward process, with
increased SLC7A2 transcription followed by increased abun-
dance of CAT2 proteins and transport stimulation. Interestingly,
the immunocytochemical analysis indicates that in cells
stimulated with both TNFα and rapamycin, most transporters
have an intracellular distribution, although a clear cut positivity
1486 R. Visigalli et al. / Biochimica et Biophysica Acta 1768 (2007) 1479–1487of plasma membrane is also detected, a finding thus far
unreported for CAT2 transporters.
Under basal conditions the expression of CAT2 proteins is
very low and, hence, their contribution to arginine transport
should be negligible. However, given that mTOR inhibition
does not change the expression of CAT1, the 2–3 fold
stimulation of arginine transport detected in cells treated with
both compounds is only ascribable to the induction of CAT2
transporters that, under these conditions, account for a
substantial portion of arginine influx. Both CAT2 isoforms,
the high affinity CAT2B and the low affinity CAT2A
(Km=5 mM), are induced by rapamycin and, more markedly,
by the combined treatment with the mTOR inhibitor and TNFα.
However, the significance of CAT2A induction remains unclear
since, even at the supraphysiological arginine concentration of
the culture medium (0.3 mM vs. normal plasma concentrations
ranging around 0.1 mM), the kinetic parameters (see Fig. 3)
indicate that no more than 20% of arginine influx in cells treated
with both rapamycin and TNFα occurs through CAT2A, with
the remaining 80% attributable to CAT2B and CAT1 activity.
Nevertheless, the induction of the low affinity CAT2A
isoform appears of particular interest. In control, untreated
endothelial cells SLC7A2/CAT2A mRNAwas undetectable [8],
suggesting that the expression of the low affinity isoform is, at
best, marginal under basal conditions. High constitutive
expression of CAT2A has been described only in hepatocytes,
while the induction of the transporter by cytokines has been
reported in other animal cell models, such as rat cardiac
myocytes [32] or rat vascular smooth muscle cells [33].
Moreover, CAT2A expression is induced also in rat skeletal
muscle under stress conditions, such as surgical trauma or food
deprivation [34]. It has been proposed that CAT2A could act as
an export route for arginine derived from the breakdown of
proteins [35]. This hypothesis appears of great interest since
rapamycin is known to induce autophagy in cultured cells
[36,37]. Thus, the increase in intracellular arginine, observed in
cells stimulated with rapamycin (see Fig. 7), could be the result
of both the increase of arginine influx, mostly due to CAT2B
expression, and the stimulation of cell proteolysis. If this is the
case, CAT2A would provide a device to prevent the excessive
accumulation of cationic amino acids in the intracellular
compartment.
More comprehensive investigations are required in order to
define the functional consequences of these changes in CAT
expression and arginine transport. Since the stimulation of
mTOR by growth factors and nutrients promotes protein
synthesis and cell growth [12–14], the inhibition of this pathway
should cause a decrease in nutrient transport. Nevertheless,
literature reports examples of inhibitory [38,39] as well as of
stimulatory [40,41] effects of rapamycin on nutrient transpor-
ters. As far as genes for arginine transporters are concerned, this
contribution represents the first investigation on the effects of
mTOR inhibition and clearly indicates that only CAT2
expression is modified by rapamycin, while CAT1, previously
linked to nutritional stimuli [42], appears unaffected, at least at
mRNA level. In non-endothelial models CAT2 induction has
been repeatedly associated with an increase in NO synthesismediated by NOS2 [43]. In contrast, the results presented here
suggest that, in human endothelium, CAT2 induction can be
uncoupled from the stimulation of NO synthesis. Indeed,
rapamycin-treated cells express CAT2 and increase the intra-
cellular arginine concentration but synthesize less NO than
untreated controls (see Fig. 7). Unpublished results from our
laboratory indicate that this effect is due to the inhibition of
NOS3 expression by rapamycin, while NOS2 expression is not
detectable under the same conditions (Dall’Asta, V. et al.,
manuscript in preparation). Given the important protective role
of NOS3-derived NO in the vascular endothelium, these results
point to the relevance of mTOR activity for the preservation of
endothelial function and viability.
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